Pacific Edge

No formal revenue or earnings targets, and no forward-work disclosure, are provided in the supplied material. The shape data show HY24 delivered 54.8% of FY24 operating revenue and 51.6% of FY24 NPAT, implying a slightly first-half-weighted year; the implied 2H24 revenue of $10.8m is lower than the $13.1m HY24 print. That cuts against a simple "momentum into FY25" read and the release does not quantify any FY25 guideposts. Management references a cash runway to a future date, but the specific endpoint is not captured in the excerpts supplied.

• What is the disclosed cash-runway date, and does it assume current revenue run-rate, the 2H24 ASP, or further cost action?
• Why did implied 2H24 revenue ($10.8m) step down from HY24 ($13.1m) despite higher ASP — was it volume, reimbursement timing, or one-off HY items?
• The Research segment reported a -$12.3m result with no separately disclosed FY24 revenue, so the split between commercial grant/other income and loss drivers is unclear.
• With equity down 34% and cash down $4.0m, what capital-raising or cost-reduction optionality has the board flagged beyond attrition in the sales team?

This briefing cannot assess Medicare reimbursement outcomes, detailed segment revenue reconciliation, or management's specific runway date, as those disclosures are not in the supplied extraction data.